Articles tagged "Dosage"

2017 American Transplant Congress
The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing.
K. Flabouris,^1,2 S. Chadban,^1,3,4 M. Ladhani,^1,3,5 M. Cervelli,⁶ P. Clayton.^1,2,6
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia; ²School of Medicine, University of Adelaide, Adelaide, Australia; ³Sydney Medical School, University of Sydney, Sydney, Australia; ⁴Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ⁵Department of Renal Medicine, Lyell McEwin Hospital, Adelaide, Australia; ⁶Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia
Purpose: High body mass index (BMI) is associated with acute rejection after kidney transplantation. We hypothesised that weight-adjusted immunosuppression dosing is a contributing factor. We…
2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
I. Ashoor,¹ K. Martz,² R. Beyl,³ V. Dharnidharka.⁴
¹Children's Hospital, New Orleans, LA; ²EMMES Corporation, Rockville, MD; ³Pennington Biomedical Research Center, Baton Rouge, LA; ⁴Washington University, St. Louis, MO
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…
2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.
Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…
2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
S. Min, T. Daljevic, M. Lafreniere-Roula, C. Manlhiot, N. Nalli, H. Grasemann, S. Schwartz, B. Kamath, V. Ng, R. Parekh, S. Mital.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…
2017 American Transplant Congress
Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.
T. Asempa,¹ S. Hudson,² L. Rebellato,² A. Maldonado.¹
¹Vidant Medical Center, Greenville, NC; ²East Carolina University, Greenville, NC
BACKGROUND: African American (AA) patients are substantially more likely to express CYP3A5. Presence of CYP3A5 polymorphisms is an important pharmacotherapeutic consideration due to the extensive…
2017 American Transplant Congress
Tacrolimus Pharmacogenomics: Association of Genetic Variants with Clinical Factors Including Tacrolimus Requirement, Clearance, Intraindividual Variability, and Coefficient Variation.
S.-Y. Kim,¹ J. Oh,² S. Yun,² I.-J. Jang,² S.-I. Min,¹ W. Cho,¹ S. Cho,¹ S. Ahn,¹ S.-K. Min,¹ J. Ha.¹
¹Surgery, Seoul National University College of Medicine, Seoul, Korea; ²Clinical Pharmacology, Seoul National University College of Medicine, Seoul, Korea
Background: Tacrolimus, which plays a backbone in immunosuppressive therapy, has a different effect in absorption according to intraindividual and interindividual variability, and it is a…
2017 American Transplant Congress
Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
G. Gu, H. Hang, Q. Xia.
Department of Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Tacrolimus is one of the major immunosuppressants commonly used in transplant recipients. Extended-release tacrolimus is expected to have immunosuppressant effects equivalent to standard-release tacrolimus while…
2016 American Transplant Congress
Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation.
A. Diamond, Z. Khawaja, M. Simpson, S.-C. Kung, M. Akoad, J. Pomposelli, E. Pomfret.
Solid Organ Transplantation & Hepatobiliary Diseases, Lahey Hospital and Medical Center, Burlington, MA.
Lower doses of rabbit-derived antithymocyte globulin (rATG) may result in less infection and cost, but may increase the incidence of acute rejection. We compared the…
2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
J. Mühbacher,¹ B. Jilma,² M. Wahrmann,³ L. Marinova,³ F. Eskandary,³ J. Gilbert,⁴ S. Panicker,⁴ G. Böhmig.³
¹Department of Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; ³Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; ⁴True North Therapeutics, Inc., South San Francisco, CA.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…
2016 American Transplant Congress
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.
P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Novartis Institutes for Biomedical Research, Basel, Switzerland.
Background. CD40-CD154 pathway blockade significantly prolongs renal allograft survival in non-human primates (NHPs), and trials of the novel blocking, non-depleting anti-CD40 monoclonal antibody (mAb) CFZ533…